CyDex Pharmaceuticals Announces Captisol(R) Technology Used In Recently Approved New Premixed Bag Presentation Of ...

CyDex Pharmaceuticals Announces Captisol(R) Technology Used In Recently Approved New Premixed Bag Presentation Of ...
CyDex Pharmaceuticals, Inc. announced that Prism Pharmaceuticals' NEXTERONE® (amiodarone HCL) Premixed Injection, which recently received supplemental new drug application (sNDA) approval from the U.S. Food and Drug Administration, makes use of the patent-protected CyDex Captisol® technology platform. The new product is a premixed intravenous (IV) bag formulation of Prism Pharmaceuticals ...

Read more on Medical News Today

---

Orignal From: CyDex Pharmaceuticals Announces Captisol(R) Technology Used In Recently Approved New Premixed Bag Presentation Of ...